Chief Executive OfficerManuel joined the UK based Allergy Therapeutics Group in July 2009 following the successful refinancing in which Azure Ventures Limited was the main investor. Prior to this appointment, Manuel was the Principal Consultant for Biohealth LLC and CEO of International Operations of the Weinstein family’s group of companies, based in the USA. Manuel was responsible for the international development of the Weinstein family’s group of pharmaceutical companies in 20 countries (known as Corporacion Farmaceutica Recalcine, CFR). Through a combination of organic growth, M&A, Joint Ventures and Start-ups, Manuel quadrupled the turnover of the business under his responsibility in 5 years.Manuel has twenty years’ experience working in the pharmaceutical industry, primarily in America and Europe. During this time he served as Director of Corporación Drokasa in Lima, where he participated in a US$25 million AAA-rated bond issue to finance the group’s expansion plans, CEO of Laboratorios Farmindustria where he was responsible to merge the company with Pharmalab to create the biggest and leading pharmaceutical group in Peru, CEO of Laboratorios Andrómaco (Chile) where he led the group to an IPO on the Santiago Stock Exchange; and Business Development Manager for Laboratorio Chile, at that time, a leading South American Pharmaceutical Group listed in the NYSE. As Chief Executive Officer of Allergy Therapeutics, Manuel is responsible for the executive management of group operations, investor relations, and implementation of the Board’s collective decisions overseeing all operational aspects of the Group and directing the long-term strategy. During his tenure since 2009, Manuel and his team have completed a corporate turnaround increasing fifteen folds the company market cap as a result of a combination of share price increase and equity issues.